,2 The theranostic approach has emerged as a potential treatment for metastatic castration-resistant prostate cancers (mCRPCs), offering precise diagnosis and staging, and targeted therapy for patients with “high likelihood of recurrence and metastasis.”3 This is because of high expression of prostate-specific membrane antigen (PSMA) in mCRPCs.4 This evidence concerns the gene FOLH1 and prostate carcinoma.